Search for Clinical Trial Results

Sponsored By

Epithelial-myoepithelial Carcinoma - 25 Studies Found

Status Study
Recruiting Study Name: Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Condition:
  • Ovarian Clear Cell Carcinoma
  • Endometrial
    Date: 2016-07-22
    Interventions:
    • Drug: Nintedanib Nintedanib (B
Recruiting Study Name: A Study of ENMD-2076 in Ovarian Clear Cell Cancers
Condition: Ovarian Clear Cell Carcinoma
Date: 2013-07-11
Interventions: Drug: ENMD-2076
Recruiting Study Name: Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Condition:
  • Ovarian Cancer
  • Adverse Effects

Date: 2013-03-19
Interventions: Drug: Sunitinib 37.5mg everyday from D1-D28 Other Na
Completed Study Name: ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
Condition:
  • Non-Small-Cell Lung Carcinoma
  • Renal Cell Carcinoma
  • Pancrea
    Date: 2003-03-16
    Interventions: Drug: ABR-217620 Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level o
Recruiting Study Name: MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
Condition:
  • Renal Clear Cell Carcinoma
  • Renal Papillary Cell Carcinoma

    • Date: 2016-02-22
    Interventions:
    • Drug: Savolitinib Other Names:
Completed Study Name: AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
Condition: Advanced Renal Cell Carcinoma
Date: 2007-04-26
Interventions:
  • Drug: AMG 386 3 mg/kg or 10mg/
Withdrawn Study Name: Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)
Condition:
  • Endometrioid Carcinoma
  • Clear Cell Carcinoma
  • Cervical Adenocarcinoma
  • Cervical Adenosquamous Cell Carcinoma
  • Radiation: fludeoxyglucose F 18

Completed Study Name: Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Condition: Kidney Cancer
Date: 2009-02-26
Interventions:
  • Biological: aldesleukin SQ Ald
Active, not recruiting Study Name: Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition:
  • Fallopian Tube Clear Cell Adenocarcinoma
  • Ovarian Clear Cell Adenocarcinoma
  • Drug: Cabozantinib S-malate Gi
Next >>>